SMPD3: Sphingomyelin Phospholipid Breakdown and Drug Target (G55512)

Target Name: SMPD3

NCBI ID: G55512

SMPD3

SMPD3: Sphingomyelin Phospholipid Breakdown and Drug Target

Sphingomyelin phosphodiesterase 3 (SMPD3) is a protein that is expressed in various tissues throughout the body, including the brain, heart, liver, and pancreas. It is a member of the families of phospholipase C (PLC) enzymes, which are involved in the breakdown of phospholipids in cell membranes. This protein is known for its role in the production of sphingomyelin, which is a major component of cell membranes.

SMPD3 is a 12-kDa protein that is expressed in the brain, heart, liver, and pancreas. It is highly conserved, with a calculated amino acid sequence of 1,201 amino acids. SMPD3 is primarily localized to the endoplasmic reticulum (ER), where it is involved in the breaking down of sphingomyelin phospholipids. This process is critical for maintaining the integrity of the cell membrane, as sphingomyelin is involved in the regulation of various cellular processes, including inflammation, migration, and signaling.

SMPD3 has been shown to play a role in a variety of physiological processes in the body. For example, it has been shown to be involved in the regulation of inflammation in the brain, where it has been shown to play a role in the production of pro-inflammatory cytokines. Additionally, SMPD3 has been shown to be involved in the regulation of cell signaling, where it has been shown to play a role in the production of signaling molecules.

SMPD3 has also been shown to be involved in the production of sphingomyelin, which is a major component of cell membranes. This process is critical for maintaining the integrity of the cell membrane, as sphingomyelin is involved in the regulation of various cellular processes, including inflammation, migration, and signaling.

SMPD3 is also known as sphingomyelin phosphatidylinositol phosphatase (SMPD), or SMPD-1. This enzyme is involved in the production of sphingomyelin phospholipids, which are crucial for maintaining the integrity of the cell membrane. SMPD3 is a critical enzyme in the production of sphingomyelin, as it is involved in the breakdown of sphingomyelin phospholipids that are produced by other enzymes.

SMPD3 is a potential drug target for various diseases, including Alzheimer's disease, Parkinson's disease, and cardiovascular disease. For example, SMPD3 has been shown to be involved in the production of pro-inflammatory cytokines, which have been linked to the development and progression of these diseases. Additionally, SMPD3 has been shown to play a role in the regulation of cell signaling, which has been implicated in the development and progression of these diseases.

In conclusion, SMPD3 is a protein that is involved in the production of sphingomyelin phospholipids, which are crucial for maintaining the integrity of the cell membrane. SMPD3 is also known as sphingomyelin phosphatidylinositol phosphatase (SMPD), or SMPD-1, and has been shown to play a role in various physiological processes in the body. SMPD3 is a potential drug target for various diseases, including Alzheimer's disease, Parkinson's disease, and cardiovascular disease. Further research is needed to fully understand the role of SMPD3 in these diseases, as well as its potential as a drug target.

Protein Name: Sphingomyelin Phosphodiesterase 3

Functions: Catalyzes the hydrolysis of sphingomyelin to form ceramide and phosphocholine. Ceramide mediates numerous cellular functions, such as apoptosis and growth arrest, and is capable of regulating these 2 cellular events independently. Also hydrolyzes sphingosylphosphocholine. Regulates the cell cycle by acting as a growth suppressor in confluent cells. Probably acts as a regulator of postnatal development and participates in bone and dentin mineralization (PubMed:10823942, PubMed:14741383, PubMed:15051724). Binds to anionic phospholipids (APLs) such as phosphatidylserine (PS) and phosphatidic acid (PA) that modulate enzymatic activity and subcellular location. May be involved in IL-1-beta-induced JNK activation in hepatocytes (By similarity). May act as a mediator in transcriptional regulation of NOS2/iNOS via the NF-kappa-B activation under inflammatory conditions (By similarity)

The "SMPD3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMPD3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets